Company

Vaxcyte

Open roles: Explore current roles
Website: vaxcyte.com
Headquarters: 825 Industrial Road, Suite 300, San Carlos, US-CA, 94070, US
Size: 588 on LinkedIn
Founded: 2013
Industry: Biological Products, (No Diagnostic Substances)
Listed: Nasdaq: PCVX

Available roles

Associate Director, Business Operations & Digital Enablement
San Carlos, California, United States · Hybrid
Oct 19, 2026
Associate Director, Business Process Management & Operational Excellence
San Carlos, California, United States · Hybrid
Oct 15, 2026
Senior Accountant
San Carlos, California, United States · Hybrid
Oct 14, 2026
Manager, Inventory and Operations Accounting
San Carlos, California, United States · Hybrid · Contract
Oct 14, 2026
Scientist II (Contract), Analytical Development
San Carlos, California, United States · On-site · Contract · Temporary
Oct 12, 2026
Systems Engineer
San Carlos, California, United States · On-site
Oct 12, 2026
Senior Associate Scientist, Research
San Carlos, California, United States · On-site
Oct 12, 2026
Associate Scientist II, Research
San Carlos, California, United States · On-site
Oct 12, 2026
IT Operations Engineer
San Carlos, California, United States · On-site
Oct 9, 2026
Manager, Facilities Engineering
San Carlos, California, United States · On-site · Full-time
Oct 8, 2026
Associate Scientist I, Research
San Carlos, California, United States · On-site
Oct 5, 2026
Scientist I, Drug Product Analytics (Laboratory Automation)
San Carlos, California, United States · On-site
Oct 5, 2026
Senior Manager, Quality Control Operations, Global Analytics
Visp, Valais, Switzerland · Hybrid · Contract
Oct 5, 2026
Staff Scientist, Immunoassay Development
San Carlos, California, United States · On-site · Contract
Oct 2, 2026
Associate Scientist II, Immunoassay Development
San Carlos, California, United States · On-site
Oct 1, 2026
Scientist II, Upstream Polysaccharide Process Development
San Carlos, California, United States · On-site
Sep 30, 2026
Senior Scientist, Analytical Development
San Carlos, California, United States · On-site
Sep 18, 2026
Senior Manager, Clinical Quality Assurance
San Carlos, California, United States · Hybrid
Sep 16, 2026
Staff Bioprocess Engineer, MSAT, Proteins
Visp, Valais, Switzerland · Hybrid · Contract
Sep 11, 2026
Associate Director, Commercial Project Management
San Carlos, California, United States · Hybrid
Sep 11, 2026
Scientist II, Analytical Development (Contract)
San Carlos, California, United States · On-site · Contract · Temporary
Sep 8, 2026
Lab Compliance Manager
San Carlos, California, United States · Hybrid
Aug 31, 2026
Staff Engineer, Process Development and Manufacturing
San Carlos, California, United States · On-site · Contract
Aug 19, 2026
Director, Supply Chain, ERP Transformation
San Carlos, California, United States · Hybrid
Aug 5, 2026

Want help applying to Vaxcyte? Talk to Praxy

About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.